NFA
TOVX icon

Nationwide Fund Advisors’s Theriva Biologics TOVX Stock Holding History

Nationwide Fund Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5
Closed -$30K – 3261
2017
Q1 		$30K Hold
5
– – ﹤0.01% 3053
2016
Q4 		$36K Hold
5
– – ﹤0.01% 3041
2016
Q3 		$82K Hold
5
– – ﹤0.01% 2953
2016
Q2 		$86K Buy
+5
New +$94.1K ﹤0.01% 2969

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Nationwide Fund Advisors's TOVX Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 5 shares — an estimated $30K sold.

Nationwide Fund Advisors first reported a position in TOVX in Q2 2016 and held it in 4 quarters. The position peaked at $86K in Q2 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 5 Theriva Biologics shares in Q2 2017, an estimated $30K.
  • Nationwide Fund Advisors first reported a position in Theriva Biologics in Q2 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Theriva Biologics position peaked at $86K in Q2 2016.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.